Age-distribution of RSV associated LRTI OPD presentations to KDH stratified by severity category in the Study Population.

<p>Age-distribution of RSV associated LRTI OPD presentations to KDH stratified by severity category in the Study Population.</p

Relationship between disease severity and clinical features in RSV positive and RSV negative children under 5 years of age presenting to OPD of Kilifi District Hospital between May 2002 and April 2004.

<p> <b>Footnotes.</b></p>$<p>Adjusted for indrawing.</p>*<p>Significantly different.</p

Estimated age-standardized population based incidence of ARI in children per 100,000 population per year.

<p>Estimated age-standardized population based incidence of ARI in children per 100,000 population per year.</p

Prevalence of clinical features in RSV positive and RSV negative children under 5 years of age presenting to OPD of Kilifi District Hospital between May 2002 and April 2004.

<p> <b>Footnotes.</b></p>$<p>MH RR risk adjusted for ageclass.</p>*<p>Number of study participants included in this estimate.</p>∧<p>prostration was very rare and is not included in the table.</p

Flow diagram of recruitment and sample testing of children aged under 5 years presenting to Kilifi District Hospital from May 2002 to April 2004.

<p>Flow diagram of recruitment and sample testing of children aged under 5 years presenting to Kilifi District Hospital from May 2002 to April 2004.</p

The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and the cumulative proportion of mortality (dark grey) by month of age over the first year of life.

<p>The cumulative coverage of one, two and three doses of vaccine (lines of decreasing greyness) and the cumulative proportion of mortality (dark grey) by month of age over the first year of life.</p

The health care use associated with rotavirus in Kenya, by month of age, observed before (light grey bars) and predicted after (dark grey bars) introduction of a rotavirus vaccine.

<p> The panels represent the number of outpatient clinic visits (panel a), hospital admissions (b) and deaths (c). The figures are representative for both Rotarix and RotaTeq as an identical efficacy was assumed.</p

Overview assumptions cost effectiveness model in the base case.

1<p>DALYs were estimated using the formula developed by Murray et.al assuming a beta of 0.04 and a constant of 0.1685.</p

Characteristics of Rotarix and RotaTeq vaccines for the prevention of rotavirus associated diarrhoea.

<p>Characteristics of Rotarix and RotaTeq vaccines for the prevention of rotavirus associated diarrhoea.</p

Cost-effectiveness acceptability curve for Rotarix (red) and RotaTeq (black) following vaccine introduction in Kenya modelled over a five year period.

<p>The Societal Perspective (SP) is the solid line, the Health Care Perspective is marked by the dashed line.</p